In late January 2026, Halozyme Therapeutics raised its 2025 and 2026 revenue guidance to about US$1.39 billion and up to US$1.81 billion, while outlining stronger multi‑year expectations backed by its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results